A phase I trial of cytotoxic T-lymphocyte precursor-oriented peptide vaccines for colorectal carcinoma patients

In most protocols of peptide-based vaccination, no consideration has been paid to whether or not peptide-specific cytotoxic T-lymphocyte (CTL) precursors are pre-existent in cancer patients. Initiation of immune boosting through vaccination is better than that of immune priming to induce prompt and...

Descripción completa

Detalles Bibliográficos
Autores principales: Sato, Y, Maeda, Y, Shomura, H, Sasatomi, T, Takahashi, M, Une, Y, Kondo, M, Shinohara, T, Hida, N, Katagiri, K, Sato, K, Sato, M, Yamada, A, Yamana, H, Harada, M, Itoh, K, Todo, S
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2004
Materias:
Clinical
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2409683/
https://www.ncbi.nlm.nih.gov/pubmed/15054451
http://dx.doi.org/10.1038/sj.bjc.6601711

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2409683/
https://www.ncbi.nlm.nih.gov/pubmed/15054451
http://dx.doi.org/10.1038/sj.bjc.6601711

Ejemplares similares